Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-15-0413 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-15-0413 C4644682!4644682 !26420856     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26420856 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26420856 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Cancer+Res 2015 ; 21 (22 ): 5008-12 Nephropedia Template TP {{tp|p=26420856 |t=2015. Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer |pdf=|usr=}}{{26420856 }} gab.com Text Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26420856 #FOAvip Lipid kinases have largely been neglected as targets in cancer, and an increasing number of reports suggest diacylglycerol kinase alpha (DGK?) may be one with promising therapeutic potential. DGK? is one of 10 DGK family members that convert diacylglycerol (DAG) to phosphatidic acid (PA), and both DAG and PA are critical lipid second messengers in the plasma membrane. A host of important oncogenic proteins and pathways affect cancer cells in part through DGK?, including the c-Met and VEGF receptors. Others partially mediate the effects of DGK? inhibition in cancer, such as mTOR and HIF-1?. DGK? inhibition can directly impair cancer cell viability, inhibits angiogenesis, and notably may also boost T-cell activation and enhance cancer immunotherapies. Although two structurally similar inhibitors of DGK? were established decades ago, they have seen minimal in vivo usage, and it is unlikely that either of these older DGK? inhibitors will have utility for cancer. An abandoned compound that also inhibits serotonin receptors may have more translational potential as a DGK? inhibitor, but more potent and specific DGK? inhibitors are sorely needed. Other DGK family members may also provide therapeutic targets in cancer, but require further investigation. Twit Text FOAVip Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26420856 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26420856 #FOAvip English Wikipedia <ref>{{Cite pmid|26420856 }}</ref> Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer #MMPMID26420856 Purow B Clin Cancer Res 2015[Nov]; 21 (22 ): 5008-12 PMID26420856 show ga Lipid kinases have largely been neglected as targets in cancer, and an increasing number of reports suggest diacylglycerol kinase alpha (DGK?) may be one with promising therapeutic potential. DGK? is one of 10 DGK family members that convert diacylglycerol (DAG) to phosphatidic acid (PA), and both DAG and PA are critical lipid second messengers in the plasma membrane. A host of important oncogenic proteins and pathways affect cancer cells in part through DGK?, including the c-Met and VEGF receptors. Others partially mediate the effects of DGK? inhibition in cancer, such as mTOR and HIF-1?. DGK? inhibition can directly impair cancer cell viability, inhibits angiogenesis, and notably may also boost T-cell activation and enhance cancer immunotherapies. Although two structurally similar inhibitors of DGK? were established decades ago, they have seen minimal in vivo usage, and it is unlikely that either of these older DGK? inhibitors will have utility for cancer. An abandoned compound that also inhibits serotonin receptors may have more translational potential as a DGK? inhibitor, but more potent and specific DGK? inhibitors are sorely needed. Other DGK family members may also provide therapeutic targets in cancer, but require further investigation. |*Immunotherapy [MESH] |Cell Differentiation/genetics [MESH] |Cell Survival/genetics [MESH] |Diacylglycerol Kinase/antagonists & inhibitors/chemistry/*genetics [MESH] |Enzyme Inhibitors/chemistry/*therapeutic use [MESH] |Humans [MESH] |Hypoxia-Inducible Factor 1, alpha Subunit/genetics [MESH] |Lymphocyte Activation/drug effects/immunology [MESH] |Neoplasms/*genetics/pathology/therapy [MESH] |Phosphatidic Acids/genetics [MESH] |Proto-Oncogene Proteins c-met/genetics [MESH] |Receptors, Vascular Endothelial Growth Factor/genetics [MESH] |Signal Transduction/drug effects [MESH]Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in Cancer (epmc).pdf DeepDyve Pubget Overpricing